 current statu etoposid manag small cell lung cancer etoposid schedule-depend drug excel activ small cell lung cancer sclc single-ag etoposid achiev overal respons rate schedul drug administr characterist treat popul rout etoposid administr intraven oral littl impact respons rate appropri dose adjust oral therapi combin activ agent etoposid effect manag sclc etoposid doxorubicin vincristin cyclophosphamid doxorubicin vincristin cav regimen loss efficaci etoposid cisplatin EP combin synergist effect salvag regimen cav failur regimen cav EP investig effect sclc cav EP use regimen studi date EP induct effect standard induct regimen EP potenti advantag thorac radiat therapi RT import limited-diseas patient recent pilot studi EP induct hyperfraction thorac RT surviv rate promis result ongo phase iii trial unit avail data etoposid activ agent sclc compon induct therapi patient new schedul etoposid administr warrant studi